Literature DB >> 12393734

Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.

Rosemarie A Reiter1, Paul Knöbl, Katalin Varadi, Peter L Turecek.   

Abstract

von Willebrand factor-cleaving protease (ADAMTS13) cleaves von Willebrand factor (VWF) and regulates its physiologic function. To investigate the relation between ADAMTS13 activity and VWF, we compared ADAMTS13 activity with the VWF-related parameters VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CBA), VWF-propeptide, proVWF, and VWF multimeric composition in 10 healthy volunteers and 3 patients with type 1 von Willebrand disease before and after infusing 0.3 microg/kg desmopressin. The VWF-related parameters in the volunteers increased 60 minutes after start of infusion by 3.7-fold for VWF:Ag, 7.2-fold for propeptide, and 2.2-fold for VWF:CBA. Unusually large VWF multimers and traces of proVWF appeared. The ADAMTS13 activity decreased to about half the initial value. After 24 hours values returned to baseline. Patients with type 1 von Willebrand disease showed similar results. We conclude that the inverse correlation between ADAMTS13 and VWF-related parameters suggests a consumption of ADAMTS13 after the desmopressin-induced release of higher multimers of VWF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393734     DOI: 10.1182/blood-2002-03-0814

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 2.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

3.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 4.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

5.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

6.  Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.

Authors:  Michael L Ekaney; Clemens L Bockmeyer; Maik Sossdorf; Philipp A Reuken; Florian Conradi; Tobias Schuerholz; Markus F Blaess; Scott L Friedman; Wolfgang Lösche; Michael Bauer; Ralf A Claus
Journal:  Mol Med       Date:  2015-04-03       Impact factor: 6.354

7.  Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.

Authors:  J Chen; D W Chung; J Le; M Ling; B A Konkle; J A López
Journal:  J Thromb Haemost       Date:  2013-09       Impact factor: 5.824

Review 8.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 9.  Platelets as Modulators of Liver Diseases.

Authors:  Ton Lisman; James P Luyendyk
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

Review 10.  VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.

Authors:  Michael Schwameis; Christian Schörgenhofer; Alice Assinger; Margarete M Steiner; Bernd Jilma
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.